Investment Analysts’ Recent Ratings Changes for Medpace (MEDP)

A number of research firms have changed their ratings and price targets for Medpace (NASDAQ: MEDP):

• 4/25/2026 – Medpace was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/24/2026 – Medpace had its price target lowered by Royal Bank Of Canada from $522.00 to $484.00. They now have an “outperform” rating on the stock.
• 4/24/2026 – Medpace had its price target lowered by Barclays PLC from $500.00 to $450.00. They now have an “equal weight” rating on the stock.
• 4/24/2026 – Medpace had its price target lowered by BMO Capital Markets from $460.00 to $400.00. They now have a “market perform” rating on the stock.
• 4/24/2026 – Medpace had its price target lowered by Robert W. Baird from $565.00 to $477.00. They now have an “outperform” rating on the stock.
• 4/6/2026 – Medpace was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.

Insider Buying and Selling

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.